The human multidrug resistance protein MRP5 transports folates and can mediate cellular resistance against antifolates

Cancer Research

Volumn 65, Issue 10, 2005, Pages 4425-4430

  Wielinga, Peter ^a   Hooijberg, Jan Hendrik ^b   Gunnarsdottir, Sjofn ^a   Kathmann, Ietje ^b   Reid, Glen ^a,d   Zelcer, Noam ^a,e   Van Der Born, Kasper ^b   De Haas, Marcel ^a   Van Der Heijden, Ingrid ^a   Kaspers, Gertjan ^b   Wijnholds, Jan ^c   Jansen, Gerrit ^b   Peters, Godefridus ^b   Borst, Piet ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c NETHERLANDS INSTITUTE FOR NEUROSCIENCE   (Netherlands)

^d Genesis Research & Development Corporation Ltd   (New Zealand)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; FOLIC ACID; FOLIC ACID ANTAGONIST; GW 1843; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 3; MULTIDRUG RESISTANCE PROTEIN 4; MULTIDRUG RESISTANCE PROTEIN 5; POLYGLUTAMIC ACID; RALTITREXED; TRITIUM; UNCLASSIFIED DRUG;

ARTICLE; CANCER INHIBITION; CELL STRAIN HEK293; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG TRANSPORT; EMBRYO; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MEMBRANE VESICLE; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN FAMILY;

BIOLOGICAL TRANSPORT; CELL LINE; FOLIC ACID; FOLIC ACID ANTAGONISTS; HUMANS; METHOTREXATE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; POLYGLUTAMIC ACID; SUBSTRATE SPECIFICITY;

EID: 20144382254     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-2810     Document Type: Article

References (41)

1. Konig J, Nies AT, Cui Y, Leier I, Keppler D. Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance. Biochim Biophys Acta 1999;1461:377-94.
2. Kruh GD, Belinsky MG. The MRP family of drug efflux pumps. Oncogene 2003;22:7537-52.
3. Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 2000;92:1295-302.
4. Keppler D, Leier I, Jedlitschky G. Transport of glutathione conjugates and glucuronides by the multidrug resistance proteins MRP1 and MRP2. Biol Chem 1997;378:787-91.
5. Borst P, Balzarini J, Ono N, et al. The potential impact of drug transporters on nucleoside-analog-based antiviral chemotherapy. Antiviral Res 2004;62:1-7.
6. Borst P, Elferink RO. Mammalian ABC transporters in health and disease. Annu Rev Biochem 2002;71:537-92.
7. Schinkel AH, Jonker JW. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drag Deliv Rev 2003;55:3-29.
8. Reid G, Wielinga P, Zelcer N, et al. Characterization of the transport of nucleoside analog drugs by the human multidrug resistance proteins MRP4 and MRP5. Mol Pharmacol 2003;63:1094-103.
9. Wielinga PR, Van Der Heijden I, Reid G, Beijnen JH, Wijnholds J, Borst P. Characterization of the MRP4-and MRP5-mediated transport of cyclic nucleotides from intact cells. J Biol Chem 2003;278:17664-71.
10. Wijnholds J, Mol CA, van Deemter L, et al. Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proc Natl Acad Sci U S A 2000;97:7476-81.
11. Wielinga PR, Reid G, Challa EE, et al. Thiopurine metabolism and identification of the thiopurine metabolites transported by MRP4 and MRP5 overexpressed in human embryonic kidney cells. Mol Pharmacol 2002;62:1321-31.
12. Jedlitschky G, Burchell B, Keppler D. The multidrug resistance protein 5 functions as an ATP-dependent export pump for cyclic nucleotides. J Biol Chem 2000;275:30069-74.
13. Jackman AL, Taylor GA, Gibson W, et al. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study. Cancer Res 1991;51:5579-86.
14. Hanlon MH, Ferone R. In vitro uptake, anabolism, and cellular retention of I843U89 and other benzoquinazoline inhibitors of thymidylate synthase. Cancer Res 1996;56:3301-6.
15. Bertino JR, Karnofsky memorial lecture. Ode to methotrexate. J Clin Oncol 1993;11:5-14.
16. Longo-Sorbello GS, Bertino JR. Current understanding of methotrexate pharmacology and efficacy in acute leukemias. Use of newer antifolates in clinical trials. Haematologica 2001;86:121-7.
17. Pincus T, Yazici Y, Sokka T, Aletaha D, Smolen JS. Methotrexate as the "anchor drug" for the treatment of early rheumatoid arthritis. Clin Exp Rheumatol 2003;21: S179-85.
18. Zhao R, Goldman ID. Resistance to antifolates. Oncogene 2003;22:7431-57.
19. Schoo MM, Pristupa ZB, Vickers PJ, Scrimgeour KG. Folate analogues as substrates of mammalian folylpolyglutamate synthetase. Cancer Res 1985;45:3034-41.
20. Chabner BA, Allegra CJ, Curt GA, et al. Polyglutamation of methotrexate. Is methotrexate a prodrug? J Clin Invest 1985;76:907-12.
21. Hooijberg JH, Broxterman HJ, Kool M, et al. Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res 1999;59:2532-5.
22. Ifergan I, Shafran A, Jansen G, Hooijberg JH, Scheffer GL, Assaraf YG. Folate deprivation results in the loss of breast cancer resistance protein (BCRP/ABCG2) expression: a role for bcrp in cellular folate homeostasis. J Biol Chem 2004;279:25527-34.
23. Liani E, Rothem L, Bunni MA, Smith CA, Jansen G, Assaraf YG. Loss of folylpoly-γ-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines. Int J Cancer 2003;103:587-99.
24. Mauritz R, Peters GJ, Priest DG, et al. Multiple mechanisms of resistance to methotrexate and novel antifolates in human CCRF-CEM leukemia cells and their implications for folate homeostasis. Biochem Pharmacol 2002;63:105-15.
25. Volk EL, Farley KM, Wu Y, Li F, Robey RW, Schneider E. Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance. Cancer Res 2002;62:5035-40.
26. Kool M, van der Linden M, de Haas M, et al. MHP3, an organic anion transporter able to transport anticancer drugs. Proc Natl Acad Sci U S A 1999;96:6914-9.
27. Reid G, Wielinga P, Zelcer N, et al. The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci U S A 2003;100:9244-9.
28. Jansen G, Schornagel JH, Kathmann I, Westerhof GR, Hordijk GJ, van der Laan BF. Measurement of folylpolyglutamate synthetase activity in head and neck squamous carcinoma cell lines and clinical samples using a new rapid separation procedure. Oncol Res 1992;4:299-305.
29. Stark M, Rothem L, Jansen G, Scheffer GL, Goldman ID, Assaraf YG. Antifolate resistance associated with loss of MRP1 expression and function in Chinese hamster ovary cells with markedly impaired export of folate and cholate. Mol Pharmacol 2003;64:220-7.
30. Assaraf YG, Rothem L, Hooijberg JH, et al. Loss of multidrug resistance protein 1 expression and folate efflux activity results in a highly concentrative folate transport in human leukemia cells. J Biol Chem 2003;278:6680-6.
31. Prat SE, Emerick RM, Horwitz L, et al. Multidrug resistance proteins (MRP) 2 and 5 transport and confer resistance to Alimta. Proc Am Assoc Cancer Res 2002;43:782.
32. Chen ZS, Robey RW, Belinsky MG, et al. Transport of methotrexate, methotrexate polyglutamates, and 17β-estradiol 17-(β-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport. Cancer Res 2003;63:4048-54.
33. Volk EL, Schneider E. Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res 2003;63:5538-43.
34. Cancer treatment. 4th ed. Philadelphia (PA): W.B. Saunders Company; 1995.
35. Chen ZS, Lee K, Kruh GD. Transport of cyclic nucleotides and estradiol 17-β-D-glucuronide by multidrug resistance protein 4. Resistance to 6-mercaptopurine and 6-thioguanine. J Biol Chem 2001;276:33747-54.
36. Hooijberg JH, Jansen G, Assaraf YG, et al. Folate concentration dependent transport activity of the multidrug resistance protein 1 (ABCC1). Biochem Pharmacol 2004;67:1541-8.
37. Chen ZS, Lee K, Walther S, et al. Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res 2002;62:3144-50.
38. Zeng H, Chen ZS, Belinsky MG, Rea PA, Kruh GD. Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res 2001;61:7225-32.
39. Sirotnak FM, Wendel HG, Bornmann WG, et al. Co-administration of probenecid, an inhibitor of a cMOAT/MRP-like plasma membrane ATPase, greatly enhanced the efficacy of a new 10-deazaaminopterin against human solid tumors in vivo. Clin Cancer Res 2000;6:3705-12.
40. Bakos E, Evers R, Sinko E, Varadi A, Borst P, Sarkadi B. Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions. Mol Pharmacol 2000;57:760-8.
41. van Aubel RA, Smeets PH, Peters JG, Bindels RJ, Russel FG. The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP. J Am Soc Nephrol 2002;13:595-603.